Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Ciaran McCrickard)
An unorthodox proposal for Biogen's Medicare-mandated Aduhelm trial
Biogen has gone full blitz since Medicare announced it would only cover its new Alzheimer’s drug when used in clinical trials, accusing the agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
